Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.

Garber DA, O'Mara LA, Gangadhara S, McQuoid M, Zhang X, Zheng R, Gill K, Verma M, Yu T, Johnson B, Li B, Derdeyn CA, Ibegbu C, Altman JD, Hunter E, Feinberg MB.

J Virol. 2012 Dec;86(23):12605-15. doi: 10.1128/JVI.00246-12. Epub 2012 Sep 12.

2.

Development of a DNA-MVA/HIVA vaccine for Kenya.

Hanke T, McMichael AJ, Mwau M, Wee EG, Ceberej I, Patel S, Sutton J, Tomlinson M, Samuel RV.

Vaccine. 2002 May 6;20(15):1995-8. Review.

PMID:
11983261
3.

New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview.

Girard M, Habel A, Chanel C.

C R Acad Sci III. 1999 Nov;322(11):959-66. Review.

PMID:
10646090
4.

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.

Hanke T, Goonetilleke N, McMichael AJ, Dorrell L.

J Gen Virol. 2007 Jan;88(Pt 1):1-12. Review. Erratum in: J Gen Virol. 2008 Feb;89(Pt 2):609. Goonetilleke, Nilu [added].

PMID:
17170430
5.

Recombinant MVA vaccines: dispelling the myths.

Cottingham MG, Carroll MW.

Vaccine. 2013 Sep 6;31(39):4247-51. doi: 10.1016/j.vaccine.2013.03.021. Epub 2013 Mar 21. Review.

PMID:
23523407
6.

Poxvirus vectors as HIV/AIDS vaccines in humans.

Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M.

Hum Vaccin Immunother. 2012 Sep;8(9):1192-207. doi: 10.4161/hv.20778. Epub 2012 Aug 21. Review.

7.

Recombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag.

Chin'ombe N.

Viruses. 2013 Aug 28;5(9):2062-78. doi: 10.3390/v5092062. Review.

8.

How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Klasse PJ, Sanders RW, Cerutti A, Moore JP.

AIDS Res Hum Retroviruses. 2012 Jan;28(1):1-15. doi: 10.1089/AID.2011.0053. Epub 2011 May 20. Review.

9.

Novel adenovirus vector-based vaccines for HIV-1.

Barouch DH.

Curr Opin HIV AIDS. 2010 Sep;5(5):386-90. doi: 10.1097/COH.0b013e32833cfe4c. Review.

10.

Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.

Price PJ, Torres-Domínguez LE, Brandmüller C, Sutter G, Lehmann MH.

Vaccine. 2013 Sep 6;31(39):4231-4. doi: 10.1016/j.vaccine.2013.03.017. Epub 2013 Mar 21. Review.

PMID:
23523404
11.

Enhancing poxvirus vectors vaccine immunogenicity.

García-Arriaza J, Esteban M.

Hum Vaccin Immunother. 2014;10(8):2235-44. doi: 10.4161/hv.28974. Review.

12.

Clinical development of Modified Vaccinia virus Ankara vaccines.

Gilbert SC.

Vaccine. 2013 Sep 6;31(39):4241-6. doi: 10.1016/j.vaccine.2013.03.020. Epub 2013 Mar 21. Review.

PMID:
23523410
13.

DNA/MVA Vaccines for HIV/AIDS.

Iyer SS, Amara RR.

Vaccines (Basel). 2014 Feb 28;2(1):160-78. doi: 10.3390/vaccines2010160. Review.

14.

Development of replication-competent viral vectors for HIV vaccine delivery.

Parks CL, Picker LJ, King CR.

Curr Opin HIV AIDS. 2013 Sep;8(5):402-11. doi: 10.1097/COH.0b013e328363d389. Review.

15.

Nonreplicating vectors in HIV vaccines.

Johnson JA, Barouch DH, Baden LR.

Curr Opin HIV AIDS. 2013 Sep;8(5):412-20. doi: 10.1097/COH.0b013e328363d3b7. Review.

16.

Utilizing poxviral vectored vaccines for antibody induction-progress and prospects.

Draper SJ, Cottingham MG, Gilbert SC.

Vaccine. 2013 Sep 6;31(39):4223-30. doi: 10.1016/j.vaccine.2013.05.091. Epub 2013 Jun 5. Review.

PMID:
23746455
17.

Clinical applications of attenuated MVA poxvirus strain.

Gómez CE, Perdiguero B, García-Arriaza J, Esteban M.

Expert Rev Vaccines. 2013 Dec;12(12):1395-416. doi: 10.1586/14760584.2013.845531. Epub 2013 Oct 30. Review.

PMID:
24168097
18.

Replicating and non-replicating viral vectors for vaccine development.

Robert-Guroff M.

Curr Opin Biotechnol. 2007 Dec;18(6):546-56. Epub 2007 Dec 11. Review.

19.

Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.

Goossens M, Pauwels K, Willemarck N, Breyer D.

Curr Gene Ther. 2013 Dec;13(6):413-20. Review.

20.

Therapeutic vaccines against HIV infection.

García F, León A, Gatell JM, Plana M, Gallart T.

Hum Vaccin Immunother. 2012 May;8(5):569-81. doi: 10.4161/hv.19555. Epub 2012 May 1. Review.

PMID:
22634436
Items per page

Supplemental Content

Write to the Help Desk